An IPCW Adjusted Win Statistics Approach in Clinical Trials Incorporating Equivalence Margins to Define Ties
- 17 July 2025
- journal article
- Published by Wiley in Statistics in Medicine
- Vol. 44 (15-17) , e70180
Abstract
In clinical trials, multiple outcomes of different priorities commonly occur as the patient's response may not be adequately characterized by a single outcome. Win statistics are appealing summary measures for between‐group difference at more than one endpoint. When defining the result of pairwise comparisons of a time‐to‐event endpoint, it is desirable to allow ties to account for incomplete follow‐up and not clinically meaningful difference in endpoints of interest. In this article, we propose a class of win statistics for time‐to‐event endpoints with a user‐specified equivalence margin. These win statistics are identifiable in the presence of right censoring and do not depend on the censoring distribution. We then develop estimation and inference procedures for the proposed win statistics based on inverse‐probability‐of‐censoring weighting adjustment to handle right censoring. We conduct extensive simulations to investigate the operational characteristics of the proposed procedure in the finite sample setting. A real oncology trial is used to illustrate the proposed approach.Keywords
All Related Versions
Funding Information
- National Heart, Lung, and Blood Institute (R01HL089778)
This publication has 22 references indexed in Scilit:
- Win‐loss parameters for right‐censored event data, with application to recurrent eventsStatistics in Medicine, 2023
- Utilizing restricted mean duration of response for efficacy evaluation of cancer treatmentsPharmaceutical Statistics, 2022
- Win odds: An adaptation of the win ratio to include tiesStatistics in Medicine, 2021
- Adjusting win statistics for dependent censoringPharmaceutical Statistics, 2020
- Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinomaAnnals of Oncology, 2020
- The win ratio: Impact of censoring and follow‐up time and use with nonproportional hazardsPharmaceutical Statistics, 2019
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell CarcinomaNew England Journal of Medicine, 2019
- Ixmyelocel-T for patients with ischaemic heart failure: a prospective randomised double-blind trialThe Lancet, 2016
- Generalized pairwise comparisons of prioritized outcomes in the two‐sample problemStatistics in Medicine, 2010
- Composite Outcomes in Randomized TrialsJAMA, 2003